ARDGX
Price
$26.24
Change
-$0.69 (-2.56%)
Updated
Dec 18 closing price
VIVIX
Price
$65.90
Change
-$1.70 (-2.51%)
Updated
Dec 18 closing price
Ad is loading...

ARDGX vs VIVIX

Header iconARDGX vs VIVIX Comparison
Open Charts ARDGX vs VIVIXBanner chart's image
Archer Dividend Growth
Price$26.24
Change-$0.69 (-2.56%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$65.90
Change-$1.70 (-2.51%)
VolumeN/A
CapitalizationN/A
ARDGX vs VIVIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ARDGX vs. VIVIX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDGX is a Hold and VIVIX is a Hold.

FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 195B vs. ARDGX (24.5M). ARDGX pays higher dividends than VIVIX: ARDGX (2.88) vs VIVIX (2.37). ARDGX was incepted earlier than VIVIX: ARDGX (8 years) vs VIVIX (26 years). ARDGX (10.37) and VIVIX (10.00) have comparable annual turnover. ARDGX has a lower initial minimum investment than VIVIX: ARDGX (2500) vs VIVIX (5000000). ARDGX (16.73) and VIVIX (16.43) have marching annual gain over last year. VIVIX return over 5 years is better than : 44.60 vs. ARDGX (36.28).
ARDGXVIVIXARDGX / VIVIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years26 years-
Gain YTD15.38016.03496%
Front LoadN/AN/A-
Min. Initial Investment250050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets24.5M195B0%
Annual Yield % from dividends2.882.37122%
Returns for 1 year16.7316.43102%
Returns for 3 years19.7120.4896%
Returns for 5 years36.2844.6081%
Returns for 10 yearsN/A104.87-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DUOT4.530.29
+6.84%
Duos Technologies Group
APLS34.530.87
+2.58%
Apellis Pharmaceuticals
OBT59.21-0.03
-0.05%
Orange County Bancorp
FTV75.73-1.12
-1.46%
Fortive Corp
HY52.58-0.96
-1.79%
Hyster-Yale Inc.